BACKGROUND: @entity1 with clinically localized, intermediate- or high-grade @entity1893 usually receive initial treatment with a @entity632 -containing regimen such as @entity786 , @entity632 , @entity1891 , and @entity229 ( @entity3726 ). Pilot studies suggest that eight cycles of @entity3726 alone or three cycles of @entity3726 followed by involved-field radiotherapy are effective in such @entity1 . METHODS: We compared these two approaches in a prospective, randomized, multi-institutional study. The end points were progression-free survival, overall survival, and life-threatening or fatal toxic effects. Two hundred eligible @entity1 were randomly assigned to receive @entity3726 plus radiotherapy, and 201 received @entity3726 alone. RESULTS: @entity1 treated with three cycles of @entity3726 plus radiotherapy had significantly better progression-free survival (P=0.03) and overall survival (P=0.02) than @entity1 treated with @entity3726 alone. The five-year estimates of progression-free survival for @entity1 receiving @entity3726 plus radiotherapy and for @entity1 receiving @entity3726 alone were 77 percent and 64 percent, respectively. The five-year estimates of overall survival for @entity1 receiving @entity3726 plus radiotherapy and for @entity1 receiving @entity3726 alone were 82 percent and 72 percent, respectively. The adverse effects included one @entity204 in each treatment group. Life-threatening toxic effects of any type were seen in 61 of 200 @entity1 treated with @entity3726 plus radiotherapy and in 80 of 201 @entity1 treated with @entity3726 alone (P=0.06). The left ventricular function was decreased in seven @entity1 who received @entity3726 alone, whereas no @entity299 were recorded in the group receiving @entity3726 plus radiotherapy (P=0.02). CONCLUSIONS: Three cycles of @entity3726 followed by involved-field radiotherapy are superior to eight cycles of @entity3726 alone for the treatment of localized intermediate- and high-grade @entity1893 .

Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone'] @entity3726 :: ('1649', 'Gene') :: ['CHOP'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity1891 :: ('MESH:D014750', 'Chemical') :: ['vincristine'] @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac events'] @entity1893 :: ('MESH:D008228', 'Disease') :: ["non-Hodgkin's lymphoma"] @entity204 :: ('MESH:D003643', 'Disease') :: ['death']
@entity1893 :: (MESH:D008228,Disease) :: ['non-Hodgkin's lymphoma']
